RGX-104 HCl

Research use only, not for human use.

RGX-104 is a liver X receptor (LXR) agonist with potential immunomodulating and antineoplastic activities. It modulates innate immunity via transcriptional activation of the ApoE gene.

RGX-104 is a liver X receptor (LXR) agonist with potential immunomodulating and antineoplastic activities. It modulates innate immunity via transcriptional activation of the ApoE gene.(In Vivo):Oral administration of GW3965 or RGX-104 hydrochloride to animals bearing palpable tumors significantly suppresses the growth of multiple cancer types. Strong tumor growth suppression is also observed in animals bearing large tumors. In some instances, the treatment causes partial or complete tumor regression. Responses are seen across a wide spectrum of malignancies, including lung cancer, melanoma, glioblastoma, and ovarian, renal cell, triple-negative breast, and colon cancer.

——

Oral administration of GW3965 or RGX-104 hydrochloride to animals bearing palpable tumors significantly suppresses the growth of multiple cancer types. Strong tumor growth suppression is also observed in animals bearing large tumors. In some instances, the treatment causes partial or complete tumor regression. Responses are seen across a wide spectrum of malignancies, including lung cancer, melanoma, glioblastoma, and ovarian, renal cell, triple-negative breast, and colon cancer.

SB742881

Others

Other Targets

LXR

Cancer

Lymphoma; Solid tumours

610318-03-1

632.54

C34H34Cl2F3NO3

>98% (HPLC)

DMSO: 115 mg/mL (181.81 mM)

Cl.C[C@H](CCOc1cccc(CC(O)=O)c1)N(CC(c1ccccc1)c1ccccc1)Cc1cccc(c1Cl)C(F)(F)F

——

(-20℃)

With Ice Pack

≥ 2 years